Download Files:
Products Details
Product Description
– Tipranavir-d4 is the deuterium labeled Tipranavir. Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM[1][2]. Tipranavir inhibits SARS-CoV-2 3CLpro activity[3].
Web ID
– HY-15148S
Shipping
– Room temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C31H29D4F3N2O5S
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Aoki M, et al. Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1. J Virol. 2012 Dec;86(24):13384-96.|[3]Li F, et al. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
CAS Number
– 1217819-15-2
Molecular Weight
– 606.69
SMILES
– C(CC1=CC=CC=C1)[C@]2([C@](C(C)([2H])[2H])([2H])[2H])CC(O)=C([C@H](CC)C3=CC(NS(=O)(=O)C4=CC=C(C(F)(F)F)C=N4)=CC=C3)C(=O)O2
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– 10 mM in DMSO
Target
– HIV;HIV Protease;Isotope-Labeled Compounds;SARS-CoV
Pathway
– Anti-infection;Metabolic Enzyme/Protease;Others
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
